

P&T Motion History
Biologic Drugs for Asthma and Urticaria

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
benralizumab mepolizumab omalizumab reslizumab	<p>After considering the evidence of safety, efficacy and special populations for the treatment of asthma, I move that benralizumab, mepolizumab, omalizumab, reslizumab are safe and efficacious for the treatment of their approved indications. Benralizumab, mepolizumab, and reslizumab can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Figueroa 2nd: Chew</p>	April 18, 2018	NA	NA	Passed unanimous